The fight against cancer seems to be an on going process. This deadly disease is very common in today’s society much more so than in decades of the past. We’ve all been touched by cancer in some form whether it’s directly or indirectly. Cancer Research has come along way as well as the medications that are being used for treatments. The good thing about this situation is that these advanced modern day drugs/treatments yield a higher return in the form of life.
One of the major players in Cancer Research is Biotech company Seattle Genetics. Since 1998 this organization has steadily grown and it develops some of the most innovative breakthrough therapies. Earlier this year Vice President Joe Biden stopped by company headquarters in Bothell, Washington for congratulatory purposes while Forbes Magazine listed the company as one of the top 100 fastest growing businesses in the U.S. for 2015. Seattle Genetics is by far the fastest growing company in the Seattle Metropolitan Statistical Area and hosts more than 800 employees. Antibody Drug Conjugates are what Seattle Genetics specializes in and they’ve developed one of the top (ADCs) on the market today known as ADCETRIS (brentuximab vedotin). This drug has yielded such great results with cancer patients that it has now been entered into multiple strategic licensing with companies such as GlaxoSmithKlein, AbbVie, Pfizer, and Genentech.
Can you name any other biotech with tis degree of success in such a short period of time? President and CEO Clay Siegall has done a tremendous job running the company and it is his passion that keeps the wheels turning. Dr. Clay Siegall may not be a household name, but he is well respected in the cancer research industry. The highly accomplished doctor has won numerous industry related awards, has written over 70 publications, and currently holds 15 patients. The company also has many more new drugs in the develop stages. As you can see, Seattle Genetics is at the apex of the industry and will continue to strive for greatness by saving lives.